Emery Brown

Emery Brown’s call for scientists to advocate more aggressively for government support arrives at a pivotal moment for research funding in the United States. The stakes extend far beyond the halls of academia; federal investment in science has stagnated relative to GDP over the past two decades, even as global competitors like China accelerate their commitment to research. Brown, a physician-scientist whose work bridges neuroscience and anesthesiology, is not simply pleading for more money—he is underscoring a structural imbalance in how scientific progress is sustained. When researchers themselves remain reluctant to engage in advocacy, they cede ground to political forces that may not prioritize long-term discovery or public health. The historical context here is critical. The post-World War II era saw the U.S. federal government become the primary patron of scientific research through agencies like the NIH and NSF, a model that fueled decades of innovation. But since the 1990s, inflation-adjusted funding for non-defense research has barely kept pace with economic growth, while the complexity of scientific challenges—from climate change to brain disorders—has exploded. Brown’s argument gains urgency against this backdrop, yet many scientists remain hesitant to step into the political fray, fearing perceived conflicts with objectivity or academic detachment. This reluctance has real consequences: chronic underfunding slows breakthroughs, discourages young researchers, and allows short-term priorities to dominate. Looking ahead, the question is whether Brown’s message will catalyze a cultural shift within the scientific community. Will institutions like the NIH and leading universities begin to treat advocacy as part of a researcher’s professional responsibilities, rather than an optional distraction? The stakes are high, particularly in fields like computational neuroscience, where breakthroughs depend on sustained, cross-disciplinary collaboration. Yet the path forward is murky: scientists must navigate a polarized political landscape while avoiding the perception of partisan bias. The broader trend, however, is clear—countries that fail to prioritize scientific investment risk falling behind in domains that will define the 21st century. Brown’s challenge is not just rhetorical; it is a call to action that could determine the trajectory of science itself.